We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

108 hedge funds and large institutions have $366M invested in Cytokinetics in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

591% more call options, than puts

Call options by funds: $4.32M | Put options by funds: $626K

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

21% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 29

13% more capital invested

Capital invested by funds: $323M → $366M (+$42.7M)

7% more funds holding

Funds holding: 101 → 108 (+7)

2.73% more ownership

Funds ownership: 65.48% → 68.21% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
108
Holders Change
+7
Holders Change %
+6.93%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
28
Increased
35
Reduced
29
Closed
16
Calls
$4.32M
Puts
$626K
Net Calls
+$3.7M
Net Calls Change
+$3.76M

Top Buyers

1
BlackRock
BlackRock
New York
+$35.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.34M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.91M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.13M
5
HCMT
Highland Capital Management (Texas)
Texas
+$2.51M

Top Sellers

1
BI
BVF Inc
California
-$6.91M
2
DCM
DAFNA Capital Management
California
-$2.56M
3
WA
Wasatch Advisors
Utah
-$2.09M
4
GC
Globeflex Capital
California
-$1.69M
5
CCMH
Cornerstone Capital Management Holdings
New York
-$1.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
KF
101
Krilogy Financial
Missouri
$6K – – –
FMA
102
FNY Managed Accounts
New York
$6K +$6.31K +540 New
BNP Paribas Financial Markets
103
BNP Paribas Financial Markets
France
$3.75K -$18.9K -1,613 -85%
MAM
104
Meeder Asset Management
Ohio
$3K – – –
HR
105
Howe & Rusling
New York
$2K -$269 -23 -12%
Creative Planning
106
Creative Planning
Kansas
$2K +$491 +42 +51%
US Bancorp
107
US Bancorp
Minnesota
$1K +$865 +74 New
DCM
108
DAFNA Capital Management
California
– -$2.56M -210,306 Closed
GC
109
Globeflex Capital
California
– -$1.69M -139,065 Closed
CCMH
110
Cornerstone Capital Management Holdings
New York
– -$1.1M -90,500 Closed
Norges Bank
111
Norges Bank
Norway
– -$976K -80,321 Closed
EC
112
EcoR1 Capital
California
– -$667K -54,879 Closed
ARTA
113
A.R.T. Advisors
New York
– -$394K -32,461 Closed
CLOS
114
Compagnie Lombard Odier SCmA
Switzerland
– -$243K -20,000 Closed
BCM
115
Bayesian Capital Management
New York
– -$159K -13,100 Closed
DTL
116
Dynamic Technology Lab
Singapore
– -$147K -12,102 Closed
PAM
117
Panagora Asset Management
Massachusetts
– -$137K -11,313 Closed
Citadel Advisors
118
Citadel Advisors
Florida
– -$132K -11,304 Closed
Lido Advisors
119
Lido Advisors
California
– -$134K -11,004 Closed
CCIA
120
Campbell & Co Investment Adviser
Maryland
– -$128K -10,500 Closed
Walleye Trading
121
Walleye Trading
New York
– -$10K -800 Closed
TRCT
122
Tower Research Capital (TRC)
New York
– -$6K -476 Closed
SEI Investments
123
SEI Investments
Pennsylvania
– +$269 +23 New
1 2 3 4
5

CYTK Hedge Fund Activity: Q1 2017 in Review

108 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2017, worth a combined $366M — up 13% from $323M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CYTK positions and 16 closed out — a net gain of 12 holders — while 35 added to existing stakes and 29 trimmed.

The largest buyer was BlackRock, adding an estimated $35.5M. The largest seller was BVF Inc, cutting an estimated $6.91M.

  • 108 institutional investors held Cytokinetics (CYTK) as of Q1 2017, up from 101 in Q4 2016.
  • Funds reported $366M of Cytokinetics stock for Q1 2017, up 13% quarter-over-quarter.
  • 28 funds opened new Cytokinetics positions in Q1 2017 and 16 closed out, a net change of +12 holders.
  • The largest Cytokinetics buyer in Q1 2017 was BlackRock, an estimated $35.5M added.
  • The largest Cytokinetics seller in Q1 2017 was BVF Inc, an estimated $6.91M sold.

Based on aggregated 13F filings for Q1 2017.